Clinical Topics

Veterans Study Calls for Better Guidance on Lung Cancer Treatment

by U.S. Medicine

November 19, 2018

SAN FRANCISCO—With increased imaging now detecting lung cancer nodules in sicker patients, a new report suggested that guidelines should be more directive in how to maximize benefit and minimize harm, while taking into account comorbidities and life expectancy.

The study in PLoS One pointed out that current pulmonary nodule guidelines don’t provide enough information on how to individualize follow-up for complex patients.

University of California San Francisco-led researchers sought to characterize comorbidity and life expectancy in older veterans with incidental, symptom-detected or screen-detected nodules in 2008-09 vs. 2013-14. The retrospective cohort study compared the effect of those patient factors on four-year nodule follow-up among the 2008-09 subgroup.

The study, conducted at an urban VAMC, focused on 243 veterans 65 and older with newly diagnosed pulmonary nodules in 2008-09—followed for four years through 2012 or 2013—and 446 older veterans diagnosed in 2013-14.

Defined as the primary outcome was receipt of any follow-up nodule imaging and/or biopsy within four years after nodule diagnosis. Primary predictor variables included age, Charlson-Deyo Comorbidity Index (CCI) and life expectancy, with favorable life expectancy defined as age 65–74 with CCI 0, while limited life expectancy was defined as age 85 or older with CCI ≥1 or age 65 or older with CCI ≥4. Researchers also examined Interaction by nodule size.

The study noted that, from 2008-09 to 2013-14, the number of older veterans diagnosed with new pulmonary nodules almost doubled, including among those with severe comorbidity and limited life expectancy.

Results indicated that, overall among the 2008-09 subgroup, receipt of nodule follow-up decreased with increasing comorbidity (CCI ≥4 vs. 0: adjusted RR 0.61, 95% CI 0.39-0.95) with a trend toward decreased follow-up among those with limited life expectancy (adjusted RR 0.69, 95% CI 0.48-1.01).

“However, we detected an interaction effect with nodule size such that comorbidity and life expectancy were associated with decreased follow-up only among those with nodules ≤6 mm,” the researchers wrote.

They added, “We found some individualization of pulmonary nodule follow-up according to comorbidity and life expectancy in older veterans with smaller nodules only.”

Related Articles

Better Survival for NSCLC Patients Treated by Military Medicine

Does universal healthcare access provided by the MHS translate into improved patient outcomes for non-small cell lung cancer?

Increasing Usage of SSRIs for Dementia Symptoms

Emerging data has suggested effectiveness for selective serotonin reuptake inhibitors for treatment of behavioral and psychological symptoms of dementia.

U.S. Medicine Recommends

More From oncology


Better Survival for NSCLC Patients Treated by Military Medicine

Does universal healthcare access provided by the MHS translate into improved patient outcomes for non-small cell lung cancer?


VA/National Cancer Institute Partnership Increases Veteran Access to Trials

Thanks to a new partnership between the National Cancer Institute and the VA, veterans with cancer will now have greater access to potentially lifesaving clinical trials.


VA Continues Hepatocellular Screening, but Study Questions the Value

Although a recent study determined that screening veterans with cirrhosis for hepatocellular carcinoma did not reduce the risk of death associated with liver cancer, the VA has no plans to change its screening practices.


Testosterone Therapy Not Linked to Aggressive Prostate Cancer in Veterans

Clinicians prescribing supplemental testosterone in men with low levels always have a nagging concern about the possible link between increasing hormone levels and prostate cancer.


Side-effects Differ Between Radiation Therapies for Prostate Cancer

A recent study compared patient-reported disease-specific functional outcomes after external beam radiation therapy (EBRT) and EBRT combined with low-dose-rate brachytherapy prostate boost (EB-LDR) among men with localized prostate cancer.

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up